Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Bioavailability of Paltusotine (CRN00808) in Healthy Volunteers
NCT04246749Phase 1Completed
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Sep 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of paltusotine in acromegaly (2 arms), sponsored by Crinetics Pharmaceuticals. Primary endpoints: Mass balance of CRN00808 up to 21 days and Absolute bioavailability of CRN00808 at 5 days. Started Sep 2019; status: completed.
02
Drugs
paltusotine
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT04246749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246749.